MovDisordV3, Main, Exploration, bibRecord, 003A65

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients

Identifieur interne : 003A65 ( Main/Exploration ); précédent : 003A64; suivant : 003A66

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients

Auteurs : ZHI LIU [Japon] ; Ryuji Sakakibara [Japon] ; Takeo Odaka [Japon] ; Tomoyuki Uchiyama [Japon] ; Tomoyuki Uchiyama [Japon] ; Tatsuya Yamamoto [Japon] ; Takashi Ito [Japon] ; Masato Asahina [Japon] ; Kazuya Yamaguchi [Japon] ; Taketo Yamaguchi [Japon] ; Takamichi Hattori [Japon]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0363476

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Constipation, Parkinson maladie, Atrophie multisystématisée, Mosapride, Agoniste partiel, Homme, Sérotonine.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Constipation, Human, Mosapride, Multiple system atrophy, Nervous system diseases, Parkinson disease, Partial agonist, Serotonin.

Abstract

Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement <3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects.

Affiliations:

Japon

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001E58
to stream PascalFrancis, to step Curation: 000E63
to stream PascalFrancis, to step Checkpoint: 001D93
to stream Main, to step Merge: 005271
to stream Main, to step Curation: 003A65

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients</title>
<author><name sortKey="Zhi Liu" sort="Zhi Liu" uniqKey="Zhi Liu" last="Zhi Liu">ZHI LIU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Ist Internal Medicine, Chiba University</s1>
<s2>Chilia</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chilia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Ist Internal Medicine, Chiba University</s1>
<s2>Chilia</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chilia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Ist Internal Medicine, Chiba University</s1>
<s2>Chilia</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chilia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0363476</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0363476 INIST</idno>
<idno type="RBID">Pascal:05-0363476</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E58</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E63</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001D93</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Zhi Liu:mosapride:citrate:a</idno>
<idno type="wicri:Area/Main/Merge">005271</idno>
<idno type="wicri:Area/Main/Curation">003A65</idno>
<idno type="wicri:Area/Main/Exploration">003A65</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients</title>
<author><name sortKey="Zhi Liu" sort="Zhi Liu" uniqKey="Zhi Liu" last="Zhi Liu">ZHI LIU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Ist Internal Medicine, Chiba University</s1>
<s2>Chilia</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chilia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Ist Internal Medicine, Chiba University</s1>
<s2>Chilia</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chilia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Ist Internal Medicine, Chiba University</s1>
<s2>Chilia</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chilia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Chiba University</s1>
<s2>Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Chiba</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Constipation</term>
<term>Human</term>
<term>Mosapride</term>
<term>Multiple system atrophy</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Partial agonist</term>
<term>Serotonin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Constipation</term>
<term>Parkinson maladie</term>
<term>Atrophie multisystématisée</term>
<term>Mosapride</term>
<term>Agoniste partiel</term>
<term>Homme</term>
<term>Sérotonine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride, mosapride does not block K channels or D2 dopaminergic receptors. The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women; mean age, 67 years) with constipation (10 with bowel movement <3 times/week; 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had a worsening of parkinsonism or other adverse events. Thirteen patients reported subjective improvements in bowel frequency (>3 times/week, 13) and difficult defecation (13). Mosapride shortened CTT of the left colon (P < 0.01) and the total colon (P < 0.05). During rectal filling, mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude in rectal contraction (P < 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract motility, as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients without serious adverse effects.</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Zhi Liu" sort="Zhi Liu" uniqKey="Zhi Liu" last="Zhi Liu">ZHI LIU</name>
</noRegion>
<name sortKey="Asahina, Masato" sort="Asahina, Masato" uniqKey="Asahina M" first="Masato" last="Asahina">Masato Asahina</name>
<name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name>
<name sortKey="Ito, Takashi" sort="Ito, Takashi" uniqKey="Ito T" first="Takashi" last="Ito">Takashi Ito</name>
<name sortKey="Odaka, Takeo" sort="Odaka, Takeo" uniqKey="Odaka T" first="Takeo" last="Odaka">Takeo Odaka</name>
<name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
<name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
<name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name>
<name sortKey="Yamaguchi, Kazuya" sort="Yamaguchi, Kazuya" uniqKey="Yamaguchi K" first="Kazuya" last="Yamaguchi">Kazuya Yamaguchi</name>
<name sortKey="Yamaguchi, Taketo" sort="Yamaguchi, Taketo" uniqKey="Yamaguchi T" first="Taketo" last="Yamaguchi">Taketo Yamaguchi</name>
<name sortKey="Yamamoto, Tatsuya" sort="Yamamoto, Tatsuya" uniqKey="Yamamoto T" first="Tatsuya" last="Yamamoto">Tatsuya Yamamoto</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A65 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A65 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0363476
   |texte=   Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri